Compare
Merck & vs PTC Therapeutics (MRK vs PTCT)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Merck & (MRK) returned +73.9% and PTC Therapeutics (PTCT) -8.8%; so far this year the figures are +39.4% and -13.8%.
Merck & is the larger company by market value, about 66.1 times the size of PTC Therapeutics.
Revenue grew +4.9% at MRK and -35.1% at PTCT over the last year.
MRK yields 2.32%. PTCT pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| MRK | PTCT | |
|---|---|---|
| Price | $146.73 | $65.44 |
| 1-day | -0.14% | -0.35% |
| YTD | +39.40% | -13.85% |
| 1 year | +73.87% | -8.82% |
| 3 years | +42.66% | +254.69% |
| Market cap | $361.7B | $5.5B |
| P/E | 149.7 | — |
| P/S | 5.37 | 4.73 |
| P/B | 8.06 | — |
| Revenue growth | +4.90% | -35.10% |
| EPS growth | -87.10% | -116.40% |
| Gross margin % | 71.8 | 25.5 |
| Net margin % | 3.6 | -9.2 |
| ROE % | 5.5 | — |
| Debt / equity | 1.20 | — |
| FCF yield % | 4.1 | 0.0 |
| Dividend yield % | 2.32 | — |
| Beta | 0.18 | 0.82 |
| RSI (14) | 51.3 | 53.3 |
| Technical rating |